Inavolisib (Standard)
Inavolisib (Standard) is the analytical standard of Inavolisib. This product is intended for research and analytical applications. Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer[1].
Product Specifications
CAS Number
2060571-02-8
Target
Apoptosis; PI3K; Reference Standards
Related Pathways
Apoptosis; Others; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
C[C@@H](C(N)=O)NC1=CC=C(C2=NC(N3[C@H](C(F)F)COC3=O)=CN2CCO4)C4=C1
Molecular Formula
C18H19F2N5O4
Molecular Weight
407.37
References & Citations
[1]R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470043-100 1x 100 µL
P21 / WAF1 (WA-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682038-500 1x 500 µL
Gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2038), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041067-100 1x 100 µL
HLA-DRB (HLA-DRB/1067), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details